MAPK1 and cancer: In cancers where these feedback mechanisms are disrupted (Haney et al., 2016[47]; Hsu et al., 2016[54]), such as through mutations in Ras or Raf, the result is often persistent ERK activation, contributing to tumorigenesis and resistance to therapies.